Quidelortho Corpoation ($QDEL) Stock Forecast: Down 5.5% Today

What is Quidelortho Corpoation?

QuidelOrtho Corporation (QDEL) is a pharmaceuticals and biotechnology company that has been facing challenges in the market, as evidenced by its recent stock performance.

Why is Quidelortho Corpoation going down?

QDEL stock is down 5.5% on May 5, 2026 19:36

• QuidelOrtho Corp. hits a new 52-week low, indicating ongoing struggles and a significant decline in stock price. This poor performance could have contributed to the bearish movement today.
• The acquisition of LEX Diagnostics by QuidelOrtho for $100 million shows the company's efforts to expand its presence in the molecular diagnostics market. However, this news might not have been enough to offset the overall negative sentiment surrounding the company.
• The decrease in QuidelOrtho's price target by 18.10% to $29.38 suggests a revised outlook on the company's valuation, potentially leading to investor concerns and selling pressure.
• Vanguard's significant but passive investment in QuidelOrtho, holding over 4 million shares, indicates institutional interest in the company. However, this large ownership stake did not prevent the bearish movement in the stock today.

QDEL Price Chart

QDEL Technical Analysis

QDEL News

Quidel Q1 2026 earnings preview

This article provides an earnings preview for Quidel's Q1 2026 financial results. It indicates that the content is a preview for an upcoming earnings report.

https://www.msn.com/en-us/money/topstocks/quidel-q1-2026-earnings-preview/ar-AA22ogaq

QuidelOrtho Corp. Hits New 52-Week Low at $10.86 Amid Ongoing Struggles

QuidelOrtho Corp. has recorded a new 52-week low of $10.86, marking a significant 72.67% decline in its stock price over the past year. The company, a small-cap player in the Pharmaceuticals & Biotechnology sector, has consistently underperformed, reporting negative results for 12 consecutive quarters and exhibiting financial struggles such as a high debt-equity ratio and negative return on equity. This performance is notably below the S&P 500's positive return, highlighting the challenges QuidelOrtho faces in a competitive market.

https://www.marketsmojo.com/news/stocks-in-action/quidelortho-corp-hits-new-52-week-low-at-1086-amid-ongoing-struggles-3961608

LEX Diagnostics acquired by QuidelOrtho Corporation for $100m six years after launch

LEX Diagnostics, a company spun out of TTP Group, has been acquired by QuidelOrtho Corporation for $100 million. This acquisition follows the FDA 510(k) clearance and CLIA waived status for LEX VELO System, a breakthrough molecular diagnostics platform designed for ultra-fast point-of-care PCR testing for respiratory pathogens. QuidelOrtho plans a US commercial launch later this year, aiming to expand its presence in point-of-care molecular diagnostics.

https://www.cambridgeindependent.co.uk/business/lex-diagnostics-acquired-by-quidelortho-corporation-for-100-9464158/

QuidelOrtho (QDEL) price target decreased by 18.10% to 29.38

This article reports a significant decrease in QuidelOrtho's (QDEL) price target, which has been reduced by 18.10% to $29.38. This specific financial adjustment indicates a revised outlook on the company's valuation.

https://www.msn.com/en-us/money/topstocks/quidelortho-qdel-price-target-decreased-by-18-10-to-29-38/ar-AA21UOzE

Vanguard holds 4,088,168 shares of QuidelOrtho (NASDAQ: QDEL)

Vanguard Portfolio Management reported beneficial ownership of 4,088,168 shares, or 6%, of QuidelOrtho (NASDAQ: QDEL) common stock as of March 31, 2026. The filing, a Schedule 13G, indicates that Vanguard holds sole dispositive power over all these shares and sole voting power over 56,400 shares. This disclosure highlights Vanguard's significant but passive investment in the diagnostic company.

https://www.stocktitan.net/sec-filings/QDEL/schedule-13g-quidel-ortho-corp-passive-investment-disclosure-5-152a8a20d517.html

Trending Today

Shoals Technologies Group Inc. ($SHLS) Stock Forecast: Down 10.3% Today

DaVita Inc. ($DVA) Stock Forecast: Up 5.1% Today

Skyworks Solutions Inc. ($SWKS) Stock Forecast: Up 5.2% Today

Coty Inc. Class A ($COTY) Stock Forecast: Up 5.6% Today

Rockwell Automation Inc. ($ROK) Stock Forecast: Up 8.9% Today

Intel Corporation ($INTC) Stock Forecast: Up 11.7% Today

Quidelortho Corpoation ($QDEL) Stock Forecast: Down 5.5% Today

American Airlines Group Inc. ($AAL) Stock Forecast: Up 5.1% Today

IQVIA Holdings Inc. ($IQV) Stock Forecast: Up 10.0% Today

Micron Technology Inc. ($MU) Stock Forecast: Up 11.4% Today

Quidelortho Corpoation Price History

21.03.2026 - QDEL Stock was down 5.3%

• The acquisition of LEX Diagnostics aimed to enhance QuidelOrtho's rapid molecular testing capabilities, focusing on point-of-care PCR testing for respiratory infections like Influenza A, B, and COVID-19.
• Analysts are optimistic about QuidelOrtho's potential return to profitability this year, however, the company preannounced weaker-than-expected first-quarter results due to market challenges and a soft respiratory season, leading to the bearish market movement.
• Market concerns about the soft respiratory season's impact on QuidelOrtho's financial performance may be overshadowing the long-term benefits of the acquisition of LEX Diagnostics and the expansion of its diagnostics portfolio.
• Investor caution regarding the company's ability to navigate market challenges and uncertainties is reflected in the downward trend of QDEL stock price, despite the strategic acquisition.

22.03.2026 - QDEL Stock was down 8.7%

• Possible reasons for the decline in QDEL's stock price include:
• QDEL announced weaker-than-anticipated first-quarter results despite acquiring LEX Diagnostics and their advanced VELO System, hinting at potential challenges in the existing market climate.
• The subdued respiratory season and various market obstacles highlighted in the earlier announcement may have influenced investor confidence and contributed to the stock's depreciation.
• Concerns about how smoothly LEX Diagnostics will be integrated into QDEL's operations and the effectiveness of leveraging the new molecular testing platform are likely impacting investor decisions.
• The stock's proximity to its lowest point in the past 52 weeks before the acquisition could also be influencing market sentiment, leading investors to await tangible outcomes from the acquisition to restore faith in QDEL's future growth opportunities.

30.03.2026 - QDEL Stock was up 5.6%

• A noteworthy passive investment from Vanguard in QuidelOrtho indicates strong investor confidence in the company's future prospects, contributing to the bullish trend.
• The rise in QDEL shares is linked to its undervaluation according to its GF Value™, complemented by positive insider buying signals from executives.
• QuidelOrtho's acquisition of LEX Diagnostics for $100 million and obtaining FDA clearance for its VELO molecular diagnostics platform demonstrate the company's dedication to expanding its presence in the molecular diagnostics sector, fueling investor optimism.
• The acquisition of LEX Diagnostics by QuidelOrtho from TTP Group highlights the growth potential and innovation in rapid PCR technology, solidifying QuidelOrtho's market position and driving the positive movement in the stock.

30.03.2026 - QDEL Stock was up 7.7%

• QuidelOrtho's price target was lowered by 18.10% to $29.38, indicating a revised outlook on the company's valuation. Despite this adjustment, the stock price rose by 6.1% to $12.29, demonstrating investor confidence.
• Vanguard revealed holding over 4 million shares of QDEL, signifying substantial passive investment in the company, potentially boosting market optimism.
• The recent completion of QuidelOrtho's acquisition of LEX Diagnostics for $100 million from TTP Group, coupled with FDA clearance for LEX's VELO molecular diagnostics platform, signals a strategic effort to fuel growth in the molecular diagnostics market. This acquisition likely influenced investor sentiment positively.
• The transfer of LEX Diagnostics from TTP Group to QuidelOrtho underscores the potential for expanding PCR technology and the synergy between the two companies, further enhancing market confidence in QDEL's future prospects.

16.03.2026 - QDEL Stock was down 33.1%

• QuidelOrtho (QDEL) disclosed a revenue decrease for Q1 2026, attributing it to a slow respiratory season and subdued international sales, particularly in China.
• The company expects negative free cash flow for Q1 2026, largely stemming from market difficulties and delayed orders in the EMEA region.
• Despite the underwhelming financial outcomes, QuidelOrtho expresses confidence in meeting the lower end of its full-year 2026 financial projections, stressing the resilience of its core operations and cost-saving strategies in place.
• The bearish trend in QDEL's market performance is linked to the soft revenue forecast for Q1 2026, sparking investor worries about the company's near-term financial health.

23.03.2026 - QDEL Stock was down 8.3%

• Following the acquisition of LEX Diagnostics, QuidelOrtho saw a decrease in its stock performance.
• The drop in QDEL's stock value is possibly connected to the company announcing lower-than-anticipated first-quarter results due to a mild respiratory season and various market obstacles.
• Investors seem worried about the immediate financial effects on QuidelOrtho, resulting in a selloff of the stock despite the growth possibilities from the acquisition.
• The market appears to be adopting a careful stance, observing how QuidelOrtho will utilize the recent acquisition to boost its revenue and profitability in the upcoming quarters.

17.03.2026 - QDEL Stock was up 5.5%

• QDEL stock experienced a notable gain today, despite a recent 27.5% drop, leading to a year-to-date decline of 55.6%.
• Insiders purchased $0.6 million worth of shares, indicating confidence in the company's future prospects.
• Despite financial hurdles like a high debt-equity ratio and consecutive quarters of negative results, the temporary rise in stock price might be influenced by technical indicators showing a mixed picture, with some signals leaning towards bullish.
• Analyst sentiment has been mostly pessimistic, with downgrades and price target decreases, but recent insider transactions of acquiring additional shares by key personnel may have sparked optimism among investors, contributing to the bullish movement.

13.03.2026 - QDEL Stock was up 5.8%

• Despite a price target cut by UBS, Quidel's stock showed strong bullish movement, suggesting market resilience.
• The partnership with Lifotronic Technology to enhance its immunoassay portfolio possibly increased investor confidence in Quidel's growth prospects.
• Concerns arose over the impact of proposed NIH funding cuts on the demand for diagnostic solutions, contributing to a recent stock decline.
• Amid challenges in healthcare funding, Quidel's focus on non-respiratory business growth and international expansion may drive future performance.

15.03.2026 - QDEL Stock was up 6.5%

• Quidel's shares saw a 7.7% surge, showcasing a positive shift despite a previous decline from its yearly high, demonstrating growing investor confidence in the company.
• A strategic supply agreement with Lifotronic Technology to enhance its immunoassay portfolio reflects optimism about Quidel's global market competitiveness and product range.
• Concerns arose due to proposed cuts in NIH funding, causing a significant 18.0% decrease in Quidel's shares, underscoring the influence of healthcare funding policies on investor perceptions and company performance.
• Despite obstacles like reduced COVID testing revenues and organizational adjustments, Quidel's insider purchases and new partnerships indicate proactive efforts to navigate market uncertainties and propel future expansion.

29.03.2026 - QDEL Stock was down 5.2%

• Today's downward movement in QDEL's stock price may be due to investors selling off shares to lock in profits following a recent uptrend.
• Concerns over integration challenges and the potential benefits of the $100 million acquisition of LEX Diagnostics from TTP Group could be contributing to the stock's decline.
• Reports of routine equity compensation activities by QDEL's COO may have sparked uncertainty among investors about the company's financial management strategies.
• Although informative, the released podcast episode by QuidelOrtho on syphilis trends is unlikely to have directly influenced today's stock performance.

04.04.2026 - QDEL Stock was down 5.3%

• QuidelOrtho Corp. (QDEL) saw a 72.67% drop in its stock price over the past year, hitting a new 52-week low at $10.86, indicating ongoing challenges in its performance.
• The recent acquisition of LEX Diagnostics for $100 million is intended to enhance QuidelOrtho's position in point-of-care molecular diagnostics, although market reaction suggests concerns about its consistent underperformance and financial difficulties.
• A reduction in QuidelOrtho's price target by 18.10% to $29.38 reflects a revised stance on the company's value, likely contributing to the negative market movement observed.
• Despite insider purchases and anticipated positive earnings results in the upcoming announcement, the general sentiment towards QuidelOrtho remains cautious, as illustrated by analysts' "Reduce" consensus rating and recent adjustments to price targets.

05.04.2026 - QDEL Stock was down 5.5%

• QuidelOrtho Corp. hits a new 52-week low, indicating ongoing struggles and a significant decline in stock price. This poor performance could have contributed to the bearish movement today.
• The acquisition of LEX Diagnostics by QuidelOrtho for $100 million shows the company's efforts to expand its presence in the molecular diagnostics market. However, this news might not have been enough to offset the overall negative sentiment surrounding the company.
• The decrease in QuidelOrtho's price target by 18.10% to $29.38 suggests a revised outlook on the company's valuation, potentially leading to investor concerns and selling pressure.
• Vanguard's significant but passive investment in QuidelOrtho, holding over 4 million shares, indicates institutional interest in the company. However, this large ownership stake did not prevent the bearish movement in the stock today.